ALK and non-small cell lung carcinoma: However, other TKIs targeting oncogenic kinases that share a certain degree of homology with ROS1 like lorlatinib (use to treat ALK + NSCLC) or next-generation TKIs like NVL-520 have been proven to be effective in ROS1 + NSCLC patients [10, 11].